Analyst Activity – Wedbush Reiterates Buy on Clearside Biomedical (NASDAQ:CLSD)

ME Staff
-
0

Analyst Ratings For Clearside Biomedical (NASDAQ:CLSD)

Today, Wedbush reiterated its Buy rating on Clearside Biomedical (NASDAQ:CLSD).

Some recent analyst ratings include

  • 2/7/2018-Wedbush Reiterated Rating of Buy.
  • 10/25/2017-Cowen Reiterated Rating of Buy.
  • 5/25/2017-JMP Securities initiated coverage with a Mkt Outperform rating.
  • 2/24/2017-JPMorgan Chase & Co. initiated coverage with a Overweight rating.

Recent Insider Trading Activity For Clearside Biomedical (NASDAQ:CLSD)
Clearside Biomedical (NASDAQ:CLSD) has insider ownership of 20.90% and institutional ownership of 51.66%.

  • On 12/7/2017 Clay Thorp, Director, sold 5,000 with an average share price of $6.13 per share and the total transaction amounting to $30,650.00.
  • On 12/5/2017 Clay Thorp, Director, sold 15,000 with an average share price of $6.37 per share and the total transaction amounting to $95,550.00.
  • On 11/16/2017 Clay Thorp, Director, sold 35,000 with an average share price of $7.00 per share and the total transaction amounting to $245,000.00.
  • On 11/14/2017 Clay Thorp, Director, sold 15,000 with an average share price of $7.02 per share and the total transaction amounting to $105,300.00.
  • On 10/19/2017 Daniel H White, Insider, sold 8,000 with an average share price of $7.82 per share and the total transaction amounting to $62,560.00.
  • On 10/5/2017 Clay Thorp, Director, sold 35,000 with an average share price of $8.57 per share and the total transaction amounting to $299,950.00.
  • On 9/15/2017 Clay Thorp, Director, sold 24,500 with an average share price of $7.52 per share and the total transaction amounting to $184,240.00.

Recent Trading Activity for Clearside Biomedical (NASDAQ:CLSD)
Shares of Clearside Biomedical closed the previous trading session at with 6.0 shares trading hands.